Skip to main content
. 2023 Jun 21;10(24):2300881. doi: 10.1002/advs.202300881

Figure 3.

Figure 3

ANO1 is a druggable target for the targeted treatment of GI cancers. Inhibition effectiveness of CAI/BBR on the in vitro proliferation were measured with multiple A) human GC, B) EC, C) CRC cell lines, and D) mouse CRC cell line MC38. Inhibition effectiveness of CAI/BBR on the in vivo tumor growth were measure with E) an ANO1‐positive GC PDX, F) an ANO1‐negative GC PDX, and G) a GIST PDX with medium ANO1 expression. *p < 0.05. ns, not significant. Error bars, mean ± SEM.